How much does it cost to develop a new drug?

Developing new drugs is expensive and time-consuming; it can take over a decade and cost about $2.8 billion（約4500億円）.

What is UBT251 and why is it significant for Novo Nordisk?

UBT251 is an investigational medicine that mimics the action of three separate gut hormones—GLP-1, GIP, and glucagon—which could lead to significantly greater efficacy than medicines like Wegovy that target only a single hormone. The medicine has already shown highly encouraging results in studies.

What competitive advantage does Intuitive Surgical have in robotic surgery?

Intuitive Surgical leads the robotic-assisted surgery market with its da Vinci system and has access to a large data set from thousands of real-world procedures, which it is using AI to turn into valuable insights for enhancing safety, effectiveness, and device improvement.

Back to articles

Three healthcare companies are using AI partnerships to accelerate drug discovery and medical device development, positioning themselves to capitalize on expanding markets in weight management and surgical procedures.

Yahoo Finance AI22h ago5 min read

Key takeaway

Three healthcare stocks—Eli Lilly, Novo Nordisk, and Intuitive Surgical—are partnering with leading AI companies to speed up drug discovery and improve surgical device performance. AI is expected to reduce the typical drug discovery phase by a year or two, lowering costs and allowing these companies to invest more in research and development while expanding their positions in high-growth markets like weight management and robotic surgery.

Summaries like this, in your inbox every morning.

3 Key Points

What happened
Eli Lilly partnered with Nvidia to build a supercomputer for drug discovery; Novo Nordisk partnered with OpenAI to improve drug development and operations; and Intuitive Surgical is using AI to enhance the safety and effectiveness of its da Vinci robotic-assisted surgery system.
Why it matters
AI could reduce the drug discovery phase—which typically takes between three and six years—by a year or two, delivering meaningful cost savings and allowing companies like Eli Lilly to invest more in R&D and offer drugs at lower prices. For Novo Nordisk, faster development could help it recover from recent setbacks in obesity treatments. For Intuitive Surgical, AI insights from its large data set of real-world procedures could improve device performance and patient outcomes.
What to watch
Eli Lilly's progress with its AI supercomputer, Novo Nordisk's investigational medicine UBT251 (which mimics the action of three separate gut hormones) as a potential advance over single-hormone treatments, and Intuitive Surgical's integration of AI into its da Vinci system operations.

FAQ

How much does it cost to develop a new drug?: Developing new drugs is expensive and time-consuming; it can take over a decade and cost about $2.8 billion（約4500億円）.
What is UBT251 and why is it significant for Novo Nordisk?: UBT251 is an investigational medicine that mimics the action of three separate gut hormones—GLP-1, GIP, and glucagon—which could lead to significantly greater efficacy than medicines like Wegovy that target only a single hormone. The medicine has already shown highly encouraging results in studies.
What competitive advantage does Intuitive Surgical have in robotic surgery?: Intuitive Surgical leads the robotic-assisted surgery market with its da Vinci system and has access to a large data set from thousands of real-world procedures, which it is using AI to turn into valuable insights for enhancing safety, effectiveness, and device improvement.

Discussion

No discussion yet for this article

Stay ahead with AI news

Get curated AI news from 200+ sources delivered daily to your inbox. Free to use.

Get Started Free

Free · takes 30 seconds · unsubscribe anytime

5 minutes a day. The AI essentials.

200+ sources · Email / LINE / Slack

Get it free →